Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 13476 - 13484 of 13484 in total
Snubh-nm-333 F-18 is under investigation in clinical trial NCT02149017 (Phase 1 and Phase 2 Clinical Trials of SNUBH-NM-333(18F)).
Investigational
Matched Description: … Snubh-nm-333 F-18 is under investigation in clinical trial NCT02149017 (Phase 1 and Phase 2 Clinical …
Girentuximab I-124 is under investigation in clinical trial NCT01762592 (REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT).
Investigational
Matched Description: … Girentuximab I-124 is under investigation in clinical trial NCT01762592 (REDECT 2: REnal Masses: Pivotal …
PMPBB3 F-18 is under investigation in clinical trial NCT04305210 (Alzheimer's Disease: Clinical Investigation and Neuroimage Studies Including 18F-PM-PBB3 and 18f-florbetapir (AV-45) PET Examination).
Investigational
Matched Description: … PMPBB3 F-18 is under investigation in clinical trial NCT04305210 (Alzheimer's Disease: Clinical Investigation …
Methyl undecenoyl leucinate is an active ingredient in whitening creams. It is an α-MSH antagonist that inhibits melanin synthesis and tyrosinase activity and reduces expression of various melanogenic genes.
Experimental
Matched Description: … Methyl undecenoyl leucinate is an active ingredient in whitening creams. …
Di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone is under investigation in clinical trial NCT02688101 (Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With Advanced Solid Tumors).
Investigational
Matched Description: … Di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone is under investigation in clinical trial …
ONT-093 is an orally bioavailable inhibitor of P-glycoprotein (P-gp). In pre-clinical studies, ONT-093 could inhibit P-gp and reverse multidrug resistance at nM concentrations with no effect on paclitaxel pharmacokinetics.
Investigational
Matched Description: … In pre-clinical studies, ONT-093 could inhibit P-gp and reverse multidrug resistance at nM concentrations …
Selective inhibitor of SIRT1 that does not inhibit histone deacetylase (HDAC) or other sirtuin deacetylase family members (IC50 values are 98, 19600, 48700, > 100000 and > 100000 nM for SIRT1, SIRT2, SIRT3, HDAC and NADase respectively). Enhances p53 acetylation in response to DNA damaging agents.
Experimental
Matched Description: … Enhances p53 acetylation in response to DNA damaging agents. …
Investigational
Experimental
Displaying drugs 13476 - 13484 of 13484 in total